Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sawai Group President Says US Biz Exit was Due to Lack of Foresight
Sawai Group Holdings Chairman and President Mitsuo Sawai said on February 14 that the group’s decision to withdraw from the US market was the result of overestimating its potential capacity there. “In short, it was more of an inaccurate forecast…
To read the full story
Related Article
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
- Sawai’s Upsher-Smith Acquisition Completed
June 2, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
- Sawai to Buy US Generic Maker Upsher-Smith
April 20, 2017
- Sawai Gets FDA Nod for Livalo Generic
February 13, 2017
- Sawai, Kowa/Nissan Chemical Settle US Patent Suit over Livalo
February 3, 2017
- Nissan Chemical Files Livalo Patent Suit against Sawai in US
July 31, 2014
- Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
BUSINESS
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
- NTT Data, Kindai Hospital Validate RWD-Based Patient Screening Technology
May 26, 2026
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…